ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.37 Million GBP | 40.5% |
| 2022 | -10.7 Million GBP | 14.96% |
| 2021 | -12.99 Million GBP | 6.77% |
| 2020 | -13.4 Million GBP | 23.69% |
| 2019 | -17.69 Million GBP | 10.73% |
| 2018 | -20.99 Million GBP | -0.54% |
| 2017 | -19.71 Million GBP | -44.64% |
| 2016 | -13.63 Million GBP | -32.75% |
| 2015 | -10.26 Million GBP | -33.23% |
| 2014 | -7.85 Million GBP | -11.15% |
| 2013 | -6.93 Million GBP | -3.6% |
| 2012 | -6.69 Million GBP | -3.25% |
| 2011 | -6.48 Million GBP | -72.47% |
| 2010 | -6.05 Million GBP | 15.47% |
| 2009 | -4.4 Million GBP | 30.4% |
| 2008 | -6.39 Million GBP | -14.66% |
| 2007 | -5.77 Million GBP | 1.57% |
| 2006 | -6.36 Million GBP | -87.95% |
| 2005 | -3.01 Million GBP | 40.18% |
| 2004 | -2.98 Million GBP | -22.69% |
| 2003 | -4.43 Million GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.61 Million GBP | -16.92% |
| 2024 Q2 | -1.61 Million GBP | 0.0% |
| 2023 FY | - GBP | 40.5% |
| 2023 Q4 | -2.7 Million GBP | -96.51% |
| 2023 Q2 | -4.14 Million GBP | -97.66% |
| 2023 Q1 | -2.09 Million GBP | 58.17% |
| 2023 Q3 | -1.37 Million GBP | 66.76% |
| 2022 Q4 | -5.01 Million GBP | -98.02% |
| 2022 Q3 | -2.53 Million GBP | 57.07% |
| 2022 FY | - GBP | 14.96% |
| 2022 Q1 | -2.97 Million GBP | 40.52% |
| 2022 Q2 | -5.89 Million GBP | -98.32% |
| 2021 Q1 | -3.83 Million GBP | 55.01% |
| 2021 FY | - GBP | 6.77% |
| 2021 Q4 | -4.99 Million GBP | -97.78% |
| 2021 Q3 | -2.52 Million GBP | 66.82% |
| 2021 Q2 | -7.61 Million GBP | -98.38% |
| 2020 Q2 | -5.56 Million GBP | -100.07% |
| 2020 Q4 | -8.53 Million GBP | -99.37% |
| 2020 Q1 | -2.78 Million GBP | 46.82% |
| 2020 FY | - GBP | 23.69% |
| 2020 Q3 | -4.27 Million GBP | 23.12% |
| 2019 Q3 | -5.23 Million GBP | -38.51% |
| 2019 Q1 | -3.77 Million GBP | 22.2% |
| 2019 FY | - GBP | 10.73% |
| 2019 Q4 | -5.23 Million GBP | 0.0% |
| 2019 Q2 | -3.77 Million GBP | 0.0% |
| 2018 Q3 | -4.85 Million GBP | 6.96% |
| 2018 Q2 | -5.21 Million GBP | 0.0% |
| 2018 Q1 | -5.21 Million GBP | -21.79% |
| 2018 FY | - GBP | -0.54% |
| 2018 Q4 | -4.85 Million GBP | 0.0% |
| 2017 Q2 | -4.77 Million GBP | 0.0% |
| 2017 FY | - GBP | -44.64% |
| 2017 Q1 | -4.77 Million GBP | -15.53% |
| 2017 Q3 | -4.28 Million GBP | 10.37% |
| 2017 Q4 | -4.28 Million GBP | 0.0% |
| 2016 Q1 | -2.67 Million GBP | -1.4% |
| 2016 FY | - GBP | -32.75% |
| 2016 Q4 | -4.13 Million GBP | 0.0% |
| 2016 Q3 | -4.13 Million GBP | -54.42% |
| 2016 Q2 | -2.67 Million GBP | 0.0% |
| 2015 Q1 | -2.42 Million GBP | -12.57% |
| 2015 Q4 | -2.64 Million GBP | 0.0% |
| 2015 Q3 | -2.64 Million GBP | -9.08% |
| 2015 Q2 | -2.42 Million GBP | 0.0% |
| 2015 FY | - GBP | -33.23% |
| 2014 Q1 | -1.72 Million GBP | 7.23% |
| 2014 FY | - GBP | -11.15% |
| 2014 Q4 | -2.15 Million GBP | 0.0% |
| 2014 Q3 | -2.15 Million GBP | -25.09% |
| 2014 Q2 | -1.72 Million GBP | 0.0% |
| 2013 Q4 | -1.85 Million GBP | 0.0% |
| 2013 Q3 | -1.85 Million GBP | 0.0% |
| 2013 FY | - GBP | -3.6% |
| 2012 FY | - GBP | -3.25% |
| 2011 FY | - GBP | -72.47% |
| 2010 FY | - GBP | 15.47% |
| 2009 FY | - GBP | 30.4% |
| 2008 FY | - GBP | -14.66% |
| 2007 FY | - GBP | 1.57% |
| 2006 FY | - GBP | -87.95% |
| 2005 FY | - GBP | 40.18% |
| 2004 FY | - GBP | -22.69% |
| 2003 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -354.413% |
| CSL Limited | 4.78 Billion USD | 100.133% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 91.033% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -7.44% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2563.6% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 63.328% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 106.774% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -314.7% |
| Mesoblast Limited | -62.38 Million USD | 89.79% |
| Marizyme, Inc. | -34.28 Million USD | 81.419% |
| Genus plc | 73.7 Million USD | 108.643% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 3.653% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -79.588% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 27.383% |
| ContraFect Corporation | -64.99 Million USD | 90.2% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -40.736% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | 82.068% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -174.118% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1129.621% |
| Accustem Sciences Inc. | -3.74 Million USD | -70.029% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 86.792% |
| EV Biologics, Inc. | -1.26 Million USD | -402.71% |
| Q BioMed Inc. | -617.62 Thousand USD | -931.365% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 278.331% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -178.837% |
| Biomind Labs Inc. | -1.03 Million USD | -515.727% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 11.049% |
| Skye Bioscience, Inc. | -13.54 Million USD | 52.98% |
| SQZ Biotechnologies Company | -64.14 Million USD | 90.069% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -25380.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -63.993% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -140.882% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 59.861% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -907.264% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 164.493% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -328.261% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -154.6% |
| GB Sciences, Inc. | -1.41 Million USD | -348.628% |
| Alpha Cognition Inc. | -9.7 Million USD | 34.368% |
| argenx SE | -216.02 Million USD | 97.051% |
| HST Global, Inc. | -5303.00 USD | -120020.686% |
| Halberd Corporation | -74.27 Thousand USD | -8475.775% |
| Enzolytics Inc. | -2.12 Million USD | -200.184% |
| Resverlogix Corp. | -11.74 Million USD | 45.75% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -107.965% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 88.489% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 83.929% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 623.418% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -120.238% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 171.947% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 94835.277% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -324.977% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1781.431% |
| AVAX Technologies, Inc. | -6.11 Million USD | -4.21% |
| ONE Bio Corp. | 13.61 Million USD | 146.793% |
| Zenith Capital Corp. | -8.6 Million USD | 25.982% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.439% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -36465.065% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -160.376% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3518.817% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -231.613% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -209.674% |
| Agentix Corp. | -1.37 Million USD | -364.368% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -142.724% |
| Helix BioMedix, Inc. | -1.04 Million USD | -508.805% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -264.0% |
| BioStem Technologies, Inc. | -7.55 Million USD | 15.67% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3417.627% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 1645.055% |
| Cell Source, Inc. | -4.27 Million USD | -49.092% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1634.65% |
| Regen BioPharma, Inc. | 1.46 Million USD | 534.529% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -579.866% |
| NovAccess Global Inc. | -1.03 Million USD | -515.58% |
| Affymax, Inc. | -14.29 Million USD | 55.439% |
| Itoco Inc. | -1.86 Million USD | -240.825% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1577.994% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -470.789% |
| CytoDyn Inc. | -18.02 Million USD | 64.668% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -7960.332% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -51989.296% |
| Qrons Inc. | -40.08 Thousand USD | -15792.817% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1211.569% |
| SYBLEU INC | -141.57 Thousand USD | -4399.509% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1307.736% |
| Rebus Holdings, Inc. | -951 Thousand USD | -569.821% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -499.806% |
| Mobile Lads Corp. | -2.24 Million USD | -184.228% |
| International Stem Cell Corporation | 202 Thousand USD | 3253.465% |
| Bioxytran, Inc. | -3.82 Million USD | -66.748% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -12001.064% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -158.74% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 82.241% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -14055.556% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -132.652% |
| Neutra Corp. | -181.24 Thousand USD | -3414.541% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 68.401% |
| PureTech Health plc | -11.62 Million USD | 45.214% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 68.399% |
| IXICO plc | -707 Thousand USD | -800.99% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 17.111% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 86.824% |
| CSL Limited | 4.73 Billion USD | 100.135% |
| Cellectis S.A. | -92.63 Million USD | 93.124% |